Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29157
IPSCIO Record ID: 3490
The Licensing Agreement also enables the Licensee to sell the Licensed technology as a research product or subLicense the technology to other third parties as potential sources of revenue.
IPSCIO Record ID: 365047
IgA nephropathy, a rare, immune complex mediated chronic glomerular disease.
Glomerular diseases affect the filtering units of your kidney, the glomeruli. Symptoms include foamy urine, pink urine, high blood pressure and swelling in your face, hands, ankles or feet. Many diseases can cause glomerular disease. The leading cause is diabetic nephropathy.
IPSCIO Record ID: 7434
IPSCIO Record ID: 230671
Upon exercise of the option, the Company will have an exclusive, royalty-bearing right and license, including a right to sublicense, under Licensor intellectual property and joint intellectual property, to develop, manufacture, use and commercialize, including filing for, obtaining and maintaining regulatory approval for, products in all medical fields on a global basis.
The Company has met with the FDA on the first indication, Necrosis Lipoidica (NL), a chronic, disfiguring condition for which most patients do not have any treatment options. Necrobiosis lipoidica is a necrotising skin condition that usually occurs in patients with diabetes mellitus but can also be associated with rheumatoid arthritis. In the former case it may be called necrobiosis lipoidica diabeticorum (NLD).
IPSCIO Record ID: 1009
IPSCIO Record ID: 304790
IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.
Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.
IPSCIO Record ID: 234465
Dry Eye Syndrome (DES)
Focal segmental glomerulosclerosis (FSGS)
Lupus nephritis (LN)
Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye
Focal segmental glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.
Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE).
IPSCIO Record ID: 26536
IPSCIO Record ID: 256221
– an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensed Technology and Licensors rights in the Joint Technology to Exploit the Licensed Compounds and Licensed Products solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in the Field and in the Territory.
– an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensor Acquired Technology to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.
– an exclusive, including with regard to Licensor and its Affiliates, right and license and right of reference in the Territory under Licensor s and its Affiliates rights, titles and interests in and to the Regulatory Approvals, to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.
This agreement contains a non-exclusive grant-back from Licensee to Licensor.
The Lead Licensed Compound means the NHE3 inhibitor designated as RDX5791, which is the subject of the IBS-C IND and the Cardio/Renal IND, and any metabolites, salts, esters, free acid forms, crystal forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.
The patents include Patent Family I regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders;Patent Family II regarding Methods For Diverting Sodium From Systemic Circulation; Patent Family Ill regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Indanes); and, Patent Family IV regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in theTreatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Multimers).
NHE3 inhibitor programme includes the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodiumâ€“hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.
End-Stage Renal Disease (ESRD) is a medical condition in which a person's kidneys cease functioning on a permanent basis leading to the need for a regular course of long-term dialysis or a kidney transplant to maintain life.
Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.
IBS-C is a type of IBS in which the abdominal discomfort or bloating happens with constipation. Generally, constipation is when stools don't pass often enough (less than three times per week).